Varenicline

Generic Name
Varenicline
Brand Names
Champix, Chantix, Tyrvaya
Drug Type
Small Molecule
Chemical Formula
C13H13N3
CAS Number
249296-44-4
Unique Ingredient Identifier
W6HS99O8ZO
Background

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...

Indication

For use as an aid in smoking cessation.

Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.

Associated Conditions
Dry Eye Syndrome (DES)
Associated Therapies
Smoking, Cessation
Clinical Trials
Related News

Use of Varenicline for 4-weeks Prior to Quitting

First Posted Date
2008-11-11
Last Posted Date
2013-12-12
Lead Sponsor
Queen Mary University of London
Target Recruit Count
101
Registration Number
NCT00789074
Locations
🇬🇧

Tobacco Dependence Research and Treatment Unit, London, United Kingdom

Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

First Posted Date
2008-10-29
Last Posted Date
2012-07-11
Lead Sponsor
Nikki Nollen, PhD, MA
Target Recruit Count
72
Registration Number
NCT00781599
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

First Posted Date
2008-10-29
Last Posted Date
2015-06-04
Lead Sponsor
VA Boston Healthcare System
Registration Number
NCT00781755
Locations
🇺🇸

VA Boston Healthcare System Brockton Medical Center, Brockton, Massachusetts, United States

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

Phase 2
Completed
Conditions
Smoking
Interventions
Drug: placebo
Drug: naltrexone
Drug: varenicline
First Posted Date
2008-10-16
Last Posted Date
2018-04-23
Lead Sponsor
Yale University
Target Recruit Count
30
Registration Number
NCT00773422
Locations
🇺🇸

Yale Center for Clinical Investigation, Yale University, New Haven, Connecticut, United States

Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)

Completed
Conditions
Smoking Cessation
Interventions
Drug: Varenicline
First Posted Date
2008-10-15
Last Posted Date
2014-02-28
Lead Sponsor
Pfizer
Target Recruit Count
3939
Registration Number
NCT00772941

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

First Posted Date
2008-09-22
Last Posted Date
2018-08-27
Lead Sponsor
Brown University
Target Recruit Count
158
Registration Number
NCT00756275
Locations
🇺🇸

Brown University, Center for Alcohol and Addiction Studies, Providence, Rhode Island, United States

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

Phase 4
Completed
Conditions
Smoking Cessation
Interventions
Drug: varenicline
Drug: placebo
First Posted Date
2008-09-10
Last Posted Date
2010-08-31
Lead Sponsor
Pfizer
Target Recruit Count
110
Registration Number
NCT00749944
Locations
🇺🇸

Pfizer Investigational Site, San Antonio, Texas, United States

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

First Posted Date
2008-09-09
Last Posted Date
2020-11-23
Lead Sponsor
University of Minnesota
Target Recruit Count
121
Registration Number
NCT00749658
Locations
🇺🇸

University of Minnesota, Tobacco Use Research Center, Minneapolis, Minnesota, United States

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Not Applicable
Completed
Conditions
Tobacco Dependence
Interventions
Drug: placebo
Drug: varenicline
First Posted Date
2008-09-05
Last Posted Date
2013-12-16
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
163
Registration Number
NCT00747643
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Varenicline
Drug: Placebo
First Posted Date
2008-09-01
Last Posted Date
2011-11-22
Lead Sponsor
Pfizer
Target Recruit Count
66
Registration Number
NCT00744978
Locations
🇰🇷

Pfizer Investigational Site, Suwon, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy